Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T23:53:10.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing the early impact of a hospital-based health technology assessment program, smart innovation

Part of: Special Collection - Methods

Published online by Cambridge University Press:  15 July 2021

Erik J. Landaas Open the ORCID record for Erik J. Landaas [Opens in a new window] ,
Ryan N. Hansen ,
Geoffrey S. Baird  and
Sean D. Sullivan
Erik J. Landaas*
Affiliation:
The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA Strategic Sourcing and Supply Chain Management, UW Medicine, Seattle, WA, USA
Ryan N. Hansen
Affiliation:
The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA
Geoffrey S. Baird
Affiliation:
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
Sean D. Sullivan
Affiliation:
The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA
*
Author for correspondence: Erik J. Landaas, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

We evaluated the early impact of a new hospital-based health technology assessment (HB-HTA) program, called Smart Innovation, at the University of Washington Medical Center (UWMC).

Methods

We compared the UWMC's utilization trends for two surgical procedures to control hospitals by evaluating the difference before and after adoption decisions: (i) a new filter for transcatheter aortic valve replacement (TAVR) procedures that treat aortic valve stenosis and (ii) microwave ablation (MWA) for treating hepatocellular carcinoma. We used descriptive statistics to assess the difference between the UWMC and controls for TAVR and MWA procedures and multivariate difference-in-differences (DID) analyses to test for statistical significance.

Results

The UWMC experienced a 10 percent reduction in TAVR procedures compared with controls following the implementation of the TAVR Sentinel filter. The DID regression model indicated a 1.5 reduction in the number of TAVR procedures per quarter at the UWMC between the pre- and post period, which was not statistically significant (p-value: .87). The UWMC experienced a 51 percent reduction in utilization when compared with controls for MWA procedures in the pre- and post periods. The DID model for MWA indicated an 18.8 decrease in utilization per quarter during the study period for the UWMC, which was statistically significant (p-value: .0007). For MWA procedures, the UWMC experienced a $647,658 dollar reduction in total costs in the post period compared with controls.

Conclusions

When the UWMC used HB-HTA methods for technology adoption, there was a reduction in utilization and total costs when compared with controls; however, when the UWMC adopted a new technology without using HB-HTA methods, there was no difference in utilization.

Keywords

Hospital-basedTechnologyQuantitativeAssessmentDiffusion
Type
Method
Information
International Journal of Technology Assessment in Health Care , Volume 37 , Issue 1 , 2021 , e76
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sampietro-Colom, L, Martin, J. Hospital-based health technology assessment: The next frontier. New York: Springer; 2016.CrossRefGoogle Scholar
Landaas, EJ, Baird, GS, Hansen, RN, Flum, DR, Sullivan, SD. Integrating formal technology assessment into an integrated healthcare delivery system: Smart Innovation. Int J Technol Assess Health Care. 2020;36:58–63.CrossRefGoogle ScholarPubMed
Landaas, EJ, Eckel, AM, Wright, JL, Baird, GS, Hansen, RN, Sullivan, SD. Application of health technology assessment (HTA) to evaluate new laboratory tests in a health system: A case study of bladder cancer testing. Acad Pathol. 2020;7. doi:10.1177/2374289520968225.CrossRefGoogle Scholar
Gagnon, MP. Hospital-based health technology assessment: Developments to date. Pharmacoeconomics. 2014;32:819–24.CrossRefGoogle ScholarPubMed
United States Food and Drug Administration (USFDA) [Internet] Device Classification Under Section 513(f)(2)(De Novo). 2019 [cited 2020 Jan 11]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN160043.Google Scholar
ECRI [Internet] Sentinel Cerebral Protection System (Boston Scientific Corp.) for Preventing Stroke during Transcatheter Aortic Valve Replacement. 2019 [cited 2020 Oct 20]. Available from: https://www.ecri.org/components/ProductBriefs/Pages/25660.aspx.Google Scholar
United States Food and Drug Administration (USFDA) [Internet] Premarket Approval, Radiofrequency. 2021 [cited 2021 Jan 12]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P930029.Google Scholar
United States Food and Drug Administration (USFDA) [Internet] 510(k) Premarket Notification, Microwave Ablation System. 2021 [cited 2021 Jan 12]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K163118.Google Scholar
Poulou, LS, Botsa, E, Thanou, I, Ziakas, PD, Thanos, L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1054.CrossRefGoogle ScholarPubMed
Poggi, G, Tosoratti, N, Montagna, B, Picchi, C. Microwave ablation of hepatocellular carcinoma. World J Hepatol. 2015;7:2578.CrossRefGoogle ScholarPubMed
Vizient [Internet] What We Do. 2020 [cited 2020 Dec 12]. Available from: https://www.vizientinc.com/what-we-do.Google Scholar
American Hospital Association (AHA) [Internet] About the AHA. 2020 [cited 2020 Dec 12]. Available from: https://www.aha.org/about.Google Scholar
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.Google Scholar
Goldsweig, AM, Tak, HJ, Chen, L-W, Aronow, HD, Shah, B, Kolte, DS, et al. The evolving management of aortic valve disease: 5-year trends in SAVR, TAVR, and medical therapy. Am J Cardiol. 2019;124:763–71.CrossRefGoogle ScholarPubMed
Wing, C, Simon, K, Bello-Gomez, RA. Designing difference in difference studies: Best practices for public health policy research. Annu Rev Public Health. 2018;39:453–69.CrossRefGoogle ScholarPubMed
Abadie, A. Semiparametric difference-in-differences estimators. Rev Econ Stud. 2005;72:1–19.CrossRefGoogle Scholar
Supplementary material: File

Landaas et al. supplementary material

Landaas et al. supplementary material

Download Landaas et al. supplementary material(File)
File 118.5 KB